ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
Drug Design, Development and Therapy · 2023-08 · Volume 17 · 2513-2522
DOI: 10.2147/dddt.s417096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023-08. Verfasst von Hamin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea. Hauptthemen laut MEDLINE: Rivaroxaban, Neoplasm Proteins. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.
- Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
- Department of Cardiology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
- Department of Cardiology, Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
ORCID-Profile: Tae-Jin Song, Junbeom Park, Hye Sun Gwak
Zitieren
APA
Kim, H., Song, T. J., Yee, J., Kim, D. H., Park, J., & Gwak, H. S. (2023). ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug Design, Development and Therapy, Volume 17, 2513-2522. https://doi.org/10.2147/dddt.s417096
Vancouver
Kim H, Song TJ, Yee J, Kim DH, Park J, Gwak HS. ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug Design, Development and Therapy. 2023;Volume 17:2513-2522. doi:10.2147/dddt.s417096
BibTeX
@article{Kim2023,
author = {Kim, Hamin and Song, Tae-Jin and Yee, Jeong and Kim, Dong-Hyeok and Park, Junbeom and Gwak, Hye Sun},
title = {ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {2513--2522},
doi = {10.2147/dddt.s417096}
}
EUVIMED